Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Therapeutic Plasma Exchange, Rituximab, and Intravenous Immunoglobulin for Progressive Idiopathic Pulmonary Fibrosis (STRIVE II)

NCT07674745 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT07674745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07674745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Therapeutic Plasma Exchange, Rituximab, and Intravenous Immunoglobulin for Progressive Idiopathic Pulmonary Fibrosis (STRIVE II)
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
March 31, 2031
Enrollment
52 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis